LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 421

Search options

  1. Article ; Online: Q&A: Paul Workman on big data and large biases.

    Workman, Paul

    Cancer discovery

    2013  Volume 3, Issue 4, Page(s) 369

    Abstract: Paul Workman, deputy chief executive at The Institute of Cancer Research (ICR) in London and ...

    Abstract Paul Workman, deputy chief executive at The Institute of Cancer Research (ICR) in London and director of its Cancer Research UK Cancer Therapeutics Unit, talks about the promise of integrating genomic, biological, and chemical "Big Data" for cancer research.
    MeSH term(s) Academies and Institutes ; Bias ; Databases, Factual ; Drug Discovery ; Neoplasms
    Language English
    Publishing date 2013-03-28
    Publishing country United States
    Document type Interview
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-ND2013-006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Paul Workman on the challenges of cancer drug development. Interview by Katharine E. Pestell.

    Workman, Paul

    Drug discovery today

    2003  Volume 8, Issue 17, Page(s) 775–777

    MeSH term(s) Antineoplastic Agents ; Drug Design ; Drug Industry ; Research
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2003-08-08
    Publishing country England
    Document type Interview
    ZDB-ID 1324988-5
    ISSN 1878-5832 ; 1359-6446
    ISSN (online) 1878-5832
    ISSN 1359-6446
    DOI 10.1016/s1359-6446(03)02838-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4725: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Paul Workman--at the cutting edge of drug discovery (interview by Dorothy Bonn).

    Workman, P

    The Lancet. Oncology

    2003  Volume 2, Issue 2, Page(s) 113–118

    MeSH term(s) Antineoplastic Agents ; Drug Industry ; Research
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2003-02-21
    Publishing country England
    Document type Interview
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/s1470-2045(00)00230-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The NCI-60 Human Tumor Cell Line Screen: A Catalyst for Progressive Evolution of Models for Discovery and Development of Cancer Drugs.

    Workman, Paul

    Cancer research

    2023  Volume 83, Issue 19, Page(s) 3170–3173

    Abstract: Following three decades of systematic primary empirical screening against mice bearing two transplantable murine leukemias, the NCI took the bold step of switching to a radically different approach-initial screening of 10,000 diverse compounds/year ... ...

    Abstract Following three decades of systematic primary empirical screening against mice bearing two transplantable murine leukemias, the NCI took the bold step of switching to a radically different approach-initial screening of 10,000 diverse compounds/year against a panel of 60 human tumor cell lines in vitro. The establishment of the "NCI-60" screen was announced in the landmark Cancer Research article by Alley and colleagues, published in 1988, which exemplified the technological basis for the new microculture screen, operating at unprecedented scale. The underlying concept was that NCI-60 might expedite the discovery of innovative cancer drugs, especially those with predicted activity against particular solid cancers-not then possible. We discuss how NCI-60 provided a major technological advance and delivered a successful legacy for cancer research and development. While not immediately cracking the thorny problem of model-to-human tumor type prediction, NCI-60 nevertheless provided the conceptual and methodologic foundation for subsequent, much larger-scale human cancer cell panel screens with detailed molecular annotation and sophisticated informatics. Now used in modern molecular target-based drug discovery, these panels help enable the implementation of contemporary biomarker-led precision oncology. See related article by Alley and colleagues, Cancer Res 1988;48:589-601.
    MeSH term(s) Humans ; Animals ; Mice ; Drug Evaluation, Preclinical ; Feasibility Studies ; Early Detection of Cancer ; Precision Medicine ; Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Neoplasms/drug therapy ; Neoplasms/genetics
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2023-09-14
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-23-2612
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.135/5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Correction to: Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective.

    Workman, Paul

    Advances in experimental medicine and biology

    2020  Volume 1243, Page(s) C1–C2

    Abstract: The original version of the book was revised: Chapter 11 is now available open access under a CC BY 4.0 license and the copyright holder has been changed to 'The Author(s)'. ...

    Abstract The original version of the book was revised: Chapter 11 is now available open access under a CC BY 4.0 license and the copyright holder has been changed to 'The Author(s)'.
    Language English
    Publishing date 2020-09-23
    Publishing country United States
    Document type Journal Article ; Published Erratum
    ISSN 2214-8019 ; 0065-2598
    ISSN (online) 2214-8019
    ISSN 0065-2598
    DOI 10.1007/978-3-030-40204-4_12
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective.

    Workman, Paul

    Advances in experimental medicine and biology

    2020  Volume 1243, Page(s) 163–179

    Abstract: This personal perspective focuses on small-molecule inhibitors of proteostasis networks in cancer-specifically the discovery and development of chemical probes and drugs acting on the molecular chaperones HSP90 and HSP70, and on the HSF1 stress pathway. ... ...

    Abstract This personal perspective focuses on small-molecule inhibitors of proteostasis networks in cancer-specifically the discovery and development of chemical probes and drugs acting on the molecular chaperones HSP90 and HSP70, and on the HSF1 stress pathway. Emphasis is on progress made and lessons learned and a future outlook is provided. Highly potent, selective HSP90 inhibitors have proved invaluable in exploring the role of this molecular chaperone family in biology and disease pathology. Clinical activity was observed, especially in non small cell lung cancer and HER2 positive breast cancer. Optimal use of HSP90 inhibitors in oncology will likely require development of creative combination strategies. HSP70 family members have proved technically harder to drug. However, recent progress has been made towards useful chemical tool compounds and these may signpost future clinical drug candidates. The HSF1 stress pathway is strongly validated as a target for cancer therapy. HSF1 itself is a ligandless transcription factor that is extremely challenging to drug directly. HSF1 pathway inhibitors have been identified mostly by phenotypic screening, including a series of bisamides from which a clinical candidate has been identified for treatment of ovarian cancer, multiple myeloma and potentially other cancers.
    MeSH term(s) HSP70 Heat-Shock Proteins/antagonists & inhibitors ; HSP90 Heat-Shock Proteins/antagonists & inhibitors ; Heat Shock Transcription Factors/antagonists & inhibitors ; Humans ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/metabolism ; Proteostasis/drug effects
    Chemical Substances HSF1 protein, human ; HSP70 Heat-Shock Proteins ; HSP90 Heat-Shock Proteins ; Heat Shock Transcription Factors
    Language English
    Publishing date 2020-04-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 410187-X
    ISSN 0065-2598
    ISSN 0065-2598
    DOI 10.1007/978-3-030-40204-4_11
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3192: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Einzelsignatur: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Book: A trend guide to cancer therapeutics

    Workman, Paul

    exploiting the p53 pathway ; proteasome inhibitors ; epigenomics and epigenetic therapy ; targeting the ErbB receptor family ; suicide gene therapy

    (Trends in molecular medicine ; 8,4, Suppl.)

    2002  

    Author's details guest ed.: Paul Workman
    Series title Trends in molecular medicine ; 8,4, Suppl.
    Collection
    Language English
    Size S73 S. : Ill.
    Publisher Elsevier
    Publishing place Rahway, NJ
    Publishing country United States
    Document type Book
    HBZ-ID HT014038423
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 4345 -8,4,Suppl.- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2.

    Licciardello, Marco P / Workman, Paul

    Trends in pharmacological sciences

    2021  Volume 42, Issue 5, Page(s) 313–315

    Abstract: Casein kinase 2 (CK2) is highly expressed in cancer and has been considered a potential therapeutic target. Wells and colleagues developed and characterized the new CK2 inhibitor SGC-CK2-1. Unexpectedly, this potent and highly selective chemical probe ... ...

    Abstract Casein kinase 2 (CK2) is highly expressed in cancer and has been considered a potential therapeutic target. Wells and colleagues developed and characterized the new CK2 inhibitor SGC-CK2-1. Unexpectedly, this potent and highly selective chemical probe does not show broad antiproliferative activity in cancer cells.
    MeSH term(s) Casein Kinase II ; Humans ; Neoplasms/drug therapy ; Protein Kinase Inhibitors
    Chemical Substances Protein Kinase Inhibitors ; Casein Kinase II (EC 2.7.11.1)
    Language English
    Publishing date 2021-03-23
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 282846-7
    ISSN 1873-3735 ; 0165-6147
    ISSN (online) 1873-3735
    ISSN 0165-6147
    DOI 10.1016/j.tips.2021.02.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1513: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 6: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Book: New approaches in cancer pharmacology / 2

    Workman, Paul

    drug design and development

    1994  

    Author's details P. Workman (ed.)
    Collection New approaches in cancer pharmacology
    Language English
    Size 97 S. : Ill., graph. Darst.
    Publisher Springer
    Publishing place Berlin u.a.
    Document type Book
    HBZ-ID HT006441772
    ISBN 3-540-58153-7 ; 0-387-58153-7 ; 978-3-540-58153-6 ; 978-0-387-58153-8
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    1993 A 2371 -2- order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Academia and industry: Successes for UK cancer partnership.

    Workman, Paul

    Nature

    2014  Volume 510, Issue 7504, Page(s) 218

    MeSH term(s) Animals ; Drug Industry ; Humans ; Technology Transfer ; Universities/economics ; Universities/organization & administration
    Language English
    Publishing date 2014-06-12
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/510218d
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 26: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 9: Show issues
    Zs.MO 244: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top